The metabolic syndrome: Common origins of a multifactorial disorder

Postgraduate Medical Journal

Volumn 85, Issue 1009, 2009, Pages 614-621

  Bruce, K D ^a   Byrne, C D ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE;

CLINICAL EVALUATION; FATTY LIVER; HUMAN; INFLAMMATION; INTRAABDOMINAL FAT; LIPID STORAGE; MATERNAL NUTRITION; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOGENICITY; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; WORLD HEALTH ORGANIZATION;

ADIPOKINES; FEMALE; HUMANS; INTRA-ABDOMINAL FAT; METABOLIC SYNDROME X; OBESITY; PREGNANCY; PRENATAL NUTRITIONAL PHYSIOLOGICAL PHENOMENA;

EID: 73249128357     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2008.078014     Document Type: Review

References (98)

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
2. Grundy SM. Metabolic syndrome: therapeutic considerations. Handb Exp Pharmacol 2005;(170):107-33.
3. Ferrannini E. Metabolic syndrome: a solution in search of a problem. J Clin Endocrinol Metab 2007;92:396-8.
4. Reaven GM. The metabolic syndrome: is this diagnosis necessary? Am J Clin Nutr 2006;83:1237-47.
5. Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2005;48:1684-99.
6. Schindler C. The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis? Ther Adv Cardiovasc Dis 2007;1:7-26.
7. Poole R, Byrne CD. The metabolic syndrome and type 2 diabetes. Minerva Endocrinol 2005;30:139-59.
8. Pladevall M, Singal B, Williams LK, et al. A single factor underlies the metabolic syndrome: a confirmatory factor analysis. Diabetes Care 2006;29:113-22.
9. World Health Organization. WHO consultation: definition, diagnosis and clasification of diabetes mellitus and its complications. Geneva: WHO, 1999.
10. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999;16:442-3.
11. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
12. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome: a new worldwide definition. Lancet 2005 24;366:1059-62.
13. Ritchie SA, Connell JM. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis 2007;17:319-26.
14. Houston MC, Basile J, Bestermann WH, et al. Addressing the global cardiovascular risk of hypertension, dyslipidemia, and insulin resistance in the southeastern United States. Am J Med Sci 2005;329:276-91.
15. Weiss R, Dziura J, Burgert TS, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004;350:2362-74.
16. Must A, Spadano J, Coakley EH, et al. The disease burden associated with overweight and obesity. JAMA 1999;282:1523-9.
17. Grandinetti A, Chang HK, Mau MK, et al. Prevalence of glucose intolerance among Native Hawaiians in two rural communities. Native Hawaiian Health Research (NHHR) Project. Diabetes Care 1998;21:549-54.
18. Grandinetti A, Kaholokula JK, Theriault AG, et al. Prevalence of diabetes and glucose intolerance in an ethnically diverse rural community of Hawaii. Ethn Dis 2007;17:250-5.
19. Suvd J, Gerel B, Otgooloi H, et al. Glucose intolerance and associated factors in Mongolia: results of a national survey. Diabet Med 2002;19:502-8.
20. Jonsson S, Hedblad B, Engstrom G, et al. Influence of obesity on cardiovascular risk. Twenty-three-year follow-up of 22,025 men from an urban Swedish population. Int J Obes Relat Metab Disord 2002;26:1046-53.
21. Carey VJ, Walters EE, Colditz GA, et al. Body fat distribution and risk of non-insulindependent diabetes mellitus in women. The Nurses' Health Study. Am J Epidemiol 1997;145:614-19.
22. Bays H, Rodbard HW, Schorr AB, et al. Adiposopathy: treating pathogenic adipose tissue to reduce cardiovascular disease risk. Curr Treat Options Cardiovasc Med 2007;9:259-71.
23. Bays HE, Gonzalez-Campoy JM, Bray GA, et al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther 2008;6:343-68.
24. Bays HE. "Sick fat," metabolic disease, and atherosclerosis. Am J Med 2009; 122(1Suppl):S26-S37.
25. Hubert HB, Feinleib M, McNamara PM, et al. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983;67:968-77.
26. Urbina EM, Gidding SS, Bao W, et al. Association of fasting blood sugar level, insulin level, and obesity with left ventricular mass in healthy children and adolescents: The Bogalusa Heart Study. Am Heart J 1999;138:122-7.
27. Haffner SM, Stern MP, Hazuda HP, et al. Do upper-body and centralized adiposity measure different aspects of regional body-fat distribution? Relationship to noninsulin-dependent diabetes mellitus, lipids, and lipoproteins. Diabetes 1987;36:43-51.
28. Han TS, van Leer EM, Seidell JC, et al. Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. BMJ 1995;311:1401-5.
29. Fontana L, Eagon JC, Trujillo ME, et al. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007;56:1010-13.
30. McNeill AM, Rosamond WD, Girman CJ, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005;28:385-90.
31. Hansson GK, Berne GP. Atherosclerosis and the immune system. Acta Paediatr Suppl 2004;93:63-9.
32. Aljada A, Mohanty P, Ghanim H, et al. Increase in intranuclear nuclear factor kappaB and decrease in inhibitor kappaB in mononuclear cells after a mixed meal: evidence for a proinflammatory effect. Am J Clin Nutr 2004;79:682-90.
33. Dandona P, Aljada A, Chaudhuri A, et al. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005;111:1448-54.
34. Gill H, Mugo M, Whaley-Connell A, et al. The key role of insulin resistance in the cardiometabolic syndrome. Am J Med Sci 2005;330:290-4.
35. Hu G, Qiao Q, Tuomilehto J, et al. Plasma insulin and cardiovascular mortality in nondiabetic European men and women: a meta-analysis of data from eleven prospective studies. Diabetologia 2004;47:1245-56.
36. Kondo H, Shimomura I, Matsukawa Y, et al. Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes 2002;51:2325-8.
37. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett 2006 22;580:2917-21.
38. Fantuzzi G, Mazzone T. Adipose tissue and adipokines in health and disease. Illustrated edn. Totowa, NJ: Humana Press, 2007.
39. Diamant M, Lamb HJ, van de Ree MA, et al. The association between abdominal visceral fat and carotid stiffness is mediated by circulating inflammatory markers in uncomplicated type 2 diabetes. J Clin Endocrinol Metab 2005;90:1495-501.
40. Arner P. Insulin resistance in type 2 diabetes: role of the adipokines. Curr Mol Med 2005;5:333-9.
41. Trujillo ME, Scherer PE. Adiponectin: journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005;257:167-75.
42. Lindsay RS, Funahashi T, Hanson RL, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002;360:57-8.
43. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adiposespecific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595-9.
44. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930-5.
45. Combs TP, Berg AH, Obici S, et al. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 2001;108:1875-81.
46. Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001;98:2005-10.
47. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-6.
48. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adiposespecific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595-9.
49. Iwashima Y, Katsuya T, Ishikawa K, et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004;43:1318-23.
50. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;6:772-83.
51. Sowers JR, Sowers PS, Peuler JD. Role of insulin resistance and hyperinsulinemia in development of hypertension and atherosclerosis. J Lab Clin Med 1994;123:647-52.
52. Clough G, Turzyniecka M, Walter L, et al. Muscle microvascular dysfunction in central obesity is related to muscle insulin insensitivity but is not reversed by high-dose statin treatment. Diabetes 2009;58:1185-91.
53. Banerji MA, Lebowitz J, Chaiken RL, et al. Relationship of visceral adipose tissue and glucose disposal is independent of sex in black NIDDM subjects. Am J Physiol 1997;273:E425-32.
54. Tchernof A, Lamarche B, Prud'homme D, et al. The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care 1996;19:629-37.
55. Jensen MD. Role of body fat distribution and the metabolic complications of obesity. J Clin Endocrinol Metab 2008;93(11 Suppl 1):S57-63.
56. Wyne KL. Free fatty acids and type 2 diabetes mellitus. Am J Med 2003; 115(Suppl 8A):29S-36S.
57. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45:846-54.
58. Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005;42:44-52.
59. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-95.
60. Fan JG, Zhu J, Li XJ, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol 2005;43:508-14.
61. Holt HB, Wild SH, Wood PJ, et al. Non-esterified fatty acid concentrations are independently associated with hepatic steatosis in obese subjects. Diabetologia 2006;49:141-8.
62. Kotronen A, Westerbacka J, Bergholm R, et al. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 2007;92:3490-7.
63. Cortez-Pinto H, Chatham J, Chacko VP, et al. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 1999;282:1659-64.
64. Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999;84:1513-17.
65. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844-50.
66. Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in nonalcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 2008;51:1947-53.
67. Kotronen A, Yki-Jarvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008;28:27-38.
68. Cinti S, Mitchell G, Barbatelli G, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 2005;46:2347-55.
69. Kolak M, Westerbacka J, Velagapudi VR, et al. Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes 2007;56:1960-8.
70. Kanda H, Tateya S, Tamori Y, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006;116:1494-505.
71. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005;11:183-90.
72. Tilg H, Moschen AR. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab 2008;19:371-9.
73. Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005;115:1343-51.
74. Byrne CD, Olufadi R, Bruce KD, et al. Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond) 2009;116:539-64.
75. Bruce K, Cagampang F, Argenton M, et al. Maternal high fat feeding primes the development of progressive non alchoholic fatty liver disease in adult offspring. 2009.
76. Begriche K, Igoudjil A, Pessayre D, et al. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006;6:1-28.
77. Caldwell SH, Swerdlow RH, Khan EM, et al. Mitochondrial abnormalities in nonalcoholic steatohepatitis. J Hepatol 1999;31:430-4.
78. Machado M, Cortez-Pinto H. Non-alcoholic steatohepatitis and metabolic syndrome. Curr Opin Clin Nutr Metab Care 2006;9:637-42.
79. Perez-Carreras M, Del HP, Martin MA, et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 2003;38:999-1007.
80. Pessayre D. Role of mitochondria in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2007;22(Suppl 1):S20-7.
81. Serviddio G, Bellanti F, Tamborra R, et al. Alterations of hepatic ATP homeostasis and respiratory chain during development of non-alcoholic steatohepatitis in a rodent model. Eur J Clin Invest 2008;38:245-52.
82. Skulachev VP. Membrane-linked systems preventing superoxide formation. Biosci Rep 1997;17:347-66.
83. Raffaella C, Francesca B, Italia F, et al. Alterations in hepatic mitochondrial compartment in a model of obesity and insulin resistance. Obesity (Silver Spring) 2008;16:958-64.
84. Taylor PD, McConnell J, Khan IY, et al. Impaired glucose homeostasis and mitochondrial abnormalities in offspring of rats fed a fat-rich diet in pregnancy. Am J Physiol Regul Integr Comp Physiol 2005;288:R134-9.
85. Dillin A, Hsu AL, rantes-Oliveira N, et al. Rates of behavior and aging specified by mitochondrial function during development. Science 2002;298:2398-401.
86. ACOG Committee. Opinion number 315, September 2005. Obesity in pregnancy. Obstet Gynecol 2005;106:671-5.
87. King JC. Maternal obesity, metabolism, and pregnancy outcomes. Annu Rev Nutr 2006;26:271-91.
88. Jones HN, Woollett LA, Barbour N, et al. High-fat diet before and during pregnancy causes marked up-regulation of placental nutrient transport and fetal overgrowth in C57/BL6 mice. FASEB J 2009;23:271-8.
89. Ozanne SE, Hales CN. Pre- and early postnatal nongenetic determinants of type 2 diabetes. Expert Rev Mol Med 2002;4:1-14.
90. Samuelsson AM, Matthews PA, Argenton M, et al. Diet-induced obesity in female mice leads to offspring hyperphagia, adiposity, hypertension, and insulin resistance: a novel murine model of developmental programming. Hypertension 2008;51:383-92.
91. Srinivasan M, Katewa SD, Palaniyappan A, et al. Maternal high-fat diet consumption results in fetal malprogramming predisposing to the onset of metabolic syndrome-like phenotype in adulthood. Am J Physiol Endocrinol Metab 2006;291:E792-9.
92. Taylor PD, Poston L. Developmental programming of obesity in mammals. Exp Physiol 2007;92:287-98.
93. Barker DJ, Bull AR, Osmond C, et al. Fetal and placental size and risk of hypertension in adult life. BMJ 1990;301:259-62.
94. Barker DJ, Gluckman PD, Godfrey KM, et al. Fetal nutrition and cardiovascular disease in adult life. Lancet 1993;341:938-41.
95. Bispham J, Gardner DS, Gnanalingham MG, et al. Maternal nutritional programming of fetal adipose tissue development: differential effects on messenger ribonucleic acid abundance for uncoupling proteins and peroxisome proliferator-activated and prolactin receptors. Endocrinology 2005;146:3943-9.
96. Boujendar S, Reusens B, Merezak S, et al. Taurine supplementation to a low protein diet during foetal and early postnatal life restores a normal proliferation and apoptosis of rat pancreatic islets. Diabetologia 2002;45:856-66.
97. Lewis DS, Bertrand HA, McMahan CA, et al. Preweaning food intake influences the adiposity of young adult baboons. J Clin Invest 1986;78:899-905.
98. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.